| Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors D Westover, J Zugazagoitia, BC Cho, CM Lovly, L Paz-Ares Annals of oncology 29, i10-i19, 2018 | 565 | 2018 |
| Quantifying drug combination synergy along potency and efficacy axes CT Meyer, DJ Wooten, BB Paudel, J Bauer, KN Hardeman, D Westover, ... Cell systems 8 (2), 97-108. e16, 2019 | 150 | 2019 |
| SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer E Ichihara, D Westover, CB Meador, Y Yan, JA Bauer, P Lu, F Ye, A Kulick, ... Cancer research 77 (11), 2990-3000, 2017 | 125 | 2017 |
| New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies D Westover, F Li Journal of Experimental & Clinical Cancer Research 34, 1-9, 2015 | 98 | 2015 |
| On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation BP Brown, YK Zhang, D Westover, Y Yan, H Qiao, V Huang, Z Du, ... Clinical Cancer Research 25 (11), 3341-3351, 2019 | 90 | 2019 |
| FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2 … D Westover, X Ling, H Lam, J Welch, C Jin, C Gongora, M Del Rio, ... Molecular cancer 14, 1-11, 2015 | 61 | 2015 |
| Fine-needle aspiration-based patient-derived cancer organoids AE Vilgelm, K Bergdorf, M Wolf, V Bharti, R Shattuck-Brandt, A Blevins, ... Iscience 23 (8), 2020 | 38 | 2020 |
| Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity? F Li, X Ling, DL Harris, J Liao, Y Wang, D Westover, G Jiang, B Xu, ... American Journal of Cancer Research 7 (2), 370, 2017 | 36 | 2017 |
| Synergistic effect of allyl isothiocyanate (AITC) on cisplatin efficacy in vitro and in vivo X Ling, D Westover, F Cao, S Cao, X He, HR Kim, Y Zhang, DCF Chan, ... American journal of cancer research 5 (8), 2516, 2015 | 22 | 2015 |
| High-throughput drug screening of fine-needle aspiration-derived cancer organoids K Bergdorf, C Phifer, V Bharti, D Westover, J Bauer, A Vilgelm, E Lee, ... STAR protocols 1 (3), 100212, 2020 | 7 | 2020 |
| The novel camptothecin derivative and IAP inhibitor FL118 is an effective treatment for irinotecan-refractory colorectal cancer D Westover, X Ling, X Liu, H Lam, C Gongora, MD Rio, F Li Cancer Research 74 (19_Supplement), 829-829, 2014 | 2 | 2014 |
| Greening automation: Wash and Re-use of disposable 384-well liquid handling tips to enable sustainable high-throughput vaccine development B Pedrazzi, A Treyer, R Cohen, A Bowman, J Acevedo-Skrip, K Kearns, ... SLAS technology 28 (5), 375-379, 2023 | 1 | 2023 |
| Mechanisms of Osimertinib resistance in EGFR mutant lung cancer D Westover, H Qiao, E Ichihara, CB Meador, CM Lovly Journal of Thoracic Oncology 12 (8), S1546, 2017 | 1 | 2017 |
| The novel camptothecin analog and antiapoptotic protein inhibitor FL118 appears to be a great backbone platform for development of personalized anticancer drugs F Li, X Ling, D Westover, X Liu, C Jin, M Wani Cancer Research 74 (19_Supplement), 1627-1627, 2014 | 1 | 2014 |
| Utilizing Three-Dimensional Culture Methods to Improve High-Throughput Drug Screening in Anaplastic Thyroid Carcinoma K Bergdorf, JA Bauer, D Westover, C Phifer, B Murphy, DR Tyson, E Lee, ... Cancers 14 (8), 1855, 2022 | | 2022 |
| On-target resistance to mutant selective EGFR inhibitors develops in an allele-specific manner dependent on the original EGFR activating mutation Y Zhang, BP Brown, D Westover, Y Yan, H Qiao, V Huang, Z Du, JA Smith, ... Cancer Research 79 (13_Supplement), 930-930, 2019 | | 2019 |
| High-throughput drug screens in osimertinib-resistant NSCLC cell lines, using continuous high-content imaging, identify potential co-targets to overcome acquired resistance D Westover, YK Zhang, Y Yan, S Himmelberg, DR Tyson, JA Bauer, ... Cancer Research 79 (13_Supplement), 330-330, 2019 | | 2019 |
| Sustained MAPK activation as a mechanism of resistance to osimertinib plus selumetinib in models of EGFR-mutant cancer D Westover, CB Meador, E Ichihara, HF Byrd, C Eberlein, Y Yan, ... Cancer Research 77 (13_Supplement), 3160-3160, 2017 | | 2017 |
| Analyzing ring moiety additions to the A-ring of camptothecin. DA Westover, C Jin, M Wani, F Li Journal of Clinical Oncology 33 (15_suppl), e13529-e13529, 2015 | | 2015 |
| Anti-cancer activity of novel camptothecin analogues that are insensitive to ABCG2 D Westover State University of New York at Buffalo, 2015 | | 2015 |
